At a glance
ClinicalIndex Comparison Record- ✓Age 4 to 6 years (from 4th birthday through day before 7th birthday)
- ✓Healthy as established by medical history and clinical examination
- ✓Previously received 1 dose of varicella-containing vaccine in the second year of life
- ✓Previously received 1 dose of measles-, mumps-, rubella-containing vaccine in the second year of life
- ✕History of hypersensitivity to neomycin or gelatin
- ✕Immunosuppressive or immunodeficient condition confirmed or suspected by medical history and physical examination
- ✕Hypersensitivity to latex
- ✕Major congenital defects
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II, Single-blind, Randomized, Controlled Study to Evaluate the Immunogenicity and Safety of a Measles, Mumps, Rubella, Varicella Vaccine Compared With ProQuad, Administered in Healthy Children 4-6 Years of Age
In Brief
A Phase 2 clinical trial evaluating Investigational MMRV(H)NS vaccine, Investigational MM(H)RVNS vaccine, and 2 other interventions for Measles; Mumps; Rubella; Chickenpox and Measles. Completed, enrolled 801 participants across 47 sites in 5 countries.
Detailed Summary
The main purpose of this study is to assess immune response and safety of various potencies of a measles, mumps, rubella, and varicella (MMRVNS) vaccines given to healthy children of 4 to 6 years of age.
Study Details
Timeline
Interventions
1 dose of a measles, mumps, and rubella at release potency and VNS at high (H) potency vaccine administered subcutaneously.
1 dose of a measles, rubella, and varicella at release potency and mumps at high (H) potency vaccine administered subcutaneously.
1 dose of measles, mumps, rubella, and varicella, all at low (L) potency vaccine administered subcutaneously.
1 dose of a marketed measles, mumps, rubella, and varicella of Lot 1 or 1 dose of a marketed measles, mumps, rubella, and varicella of Lot 2 vaccine administered subcutaneously.